Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
Reviva Pharmaceuticals announced that the European Patent Office has granted European Patent EP3244896 for the use of brilaroxazine in treating pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH), including patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD).
This extends the company's existing patent protections in key markets such as the U.S., China, and Japan.
Brilaroxazine, which has an Orphan Drug Designation from the FDA for PAH, targets the underlying disruption in serotonin signaling responsible for PH/PAH. It has shown favorable safety and tolerability in over 800 subjects in multiple clinical trials.
Recent studies have demonstrated a significant reduction in proinflammatory biomarkers and pulmonary arterial pressure, underscoring its therapeutic potential.
Reviva aims to explore further clinical development opportunities for brilaroxazine in treating PH and PAH.
- European Patent EP3244896 granted for the use of brilaroxazine.
- Brilaroxazine patent extends to key markets including the U.S., China, and Japan.
- Favorable safety and tolerability profile shown in over 800 subjects.
- Significant reduction in proinflammatory biomarkers observed.
- Notable reduction in pulmonary arterial pressure in animal models.
- None.
Insights
The grant of a European patent for brilaroxazine's use in treating pulmonary hypertension (PH) and related conditions is a significant milestone for Reviva Pharmaceuticals. The patent further extends the intellectual property protection already in place in major markets like the U.S., China and Japan. This move can potentially safeguard Reviva's market share and discourage competition.
Brilaroxazine's novel mechanism of action targets the disruption in serotonin signaling, which plays a important role in the pathogenesis of PH and pulmonary arterial hypertension (PAH). The drug’s favorable safety and tolerability profile, demonstrated in over 800 subjects across multiple clinical trials, adds to its credibility. Moreover, the reduction in key proinflammatory biomarkers and pulmonary arterial pressure found in animal models is promising for its efficacy in humans.
For retail investors, it is essential to understand that patent protection provides a competitive edge by ensuring market exclusivity for a period, which can drive higher revenue potential. The Orphan Drug Designation by the FDA for PAH further adds economic incentives, including tax credits, grant funding and market exclusivity upon approval.
The granting of this European patent is strategically important for Reviva Pharmaceuticals’ financial health. Patent protection in multiple key markets creates a robust barrier to entry for competitors and can lead to substantial revenue streams if the drug is commercialized successfully. Additionally, having orphan drug status in the U.S. could lead to reduced R&D costs and expedited review processes, enhancing market entry efficiency.
Investors should note that the success of brilaroxazine in clinical trials and subsequent market acceptance will be critical for Reviva's future revenue growth. The drug's broad therapeutic potential in treating PH and PAH, especially in patients with conditions like COPD and SCD, opens up a wide market opportunity. This breadth can lead to diversified revenue streams, reducing financial risk.
Short-term, the news could spur a positive reaction from the market, potentially lifting the stock price as investor sentiment improves. Long-term, success in clinical trials and eventual market approval will be the real determinants of sustained financial performance.
The issuance of the European patent for brilaroxazine solidifies Reviva Pharmaceuticals' position in the competitive landscape of treatments for pulmonary hypertension. The additional patent protection in Europe complements existing patents in the U.S., China and Japan, reinforcing a global strategy to capture market share in the PH treatment segment.
Brilaroxazine’s unique multi-modal mechanism of action and promising clinical data could make it a strong contender against existing therapies. The global market for PH treatments is growing, driven by rising disease prevalence and the demand for more effective treatments. By securing early patents, Reviva places itself in a strong competitive position to capitalize on this expanding market.
Retail investors should keep an eye on the ongoing and future clinical trials, as positive results could lead to higher adoption rates and increased market penetration. The potential for brilaroxazine to address unmet medical needs in PH and related conditions like COPD and SCD makes it a compelling therapeutic candidate with substantial market potential.
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD)
-Similar patents have also been granted in key markets around the world including the United States, China, and Japan
-Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in the pathogenesis of PH/PAH
CUPERTINO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced European Patent EP3244896 has been granted by the European Patent Office (EPO) covering use of brilaroxazine for the treatment of PH, adding to its existing patent protection in key markets around the world including the United States, China and Japan. The European patent covers brilaroxazine use for treating PH and PAH in any patients and treating PH in patients with COPD or SCD. Brilaroxazine has received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of PAH.
“This latest patent further secures the broad therapeutic potential of brilaroxazine for inflammatory conditions driven by underlying disruption in serotonin signaling like pulmonary hypertension,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO. “Brilaroxazine has demonstrated a favorable clinical safety and tolerability profile in over 800 subjects to date from multiple clinical trials. A significant reduction in key proinflammatory biomarkers following brilaroxazine treatment was recently shown in a large, global, pivotal Phase 3 study in patients with schizophrenia. Building on this promising clinical data, potent anti-inflammatory and antifibrotic activities and significant reduction in pulmonary arterial pressure has been shown in translational animal models for PAH following brilaroxazine treatment, and we look forward to further evaluating brilaroxazine’s unique multi-modal mechanism of action with clinical development expansion opportunities in PH and PAH.”
About Brilaroxazine
Brilaroxazine is an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in the pathobiology of several conditions including schizophrenia, psoriasis and interstitial lung diseases like pulmonary hypertension, pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF).
Positive topline data from the global Phase 3 RECOVER-1 trial in schizophrenia demonstrated the trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains including reduction in key proinflammatory cytokines implicated in the pathobiology of schizophrenia and comorbid inflammatory conditions at week 4 with 50 mg of brilaroxazine vs. placebo with a generally well-tolerated side effect profile comparable to placebo and discontinuation rates lower than placebo. Positive data from a clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects supports no clinically significant interaction when combined with a CYP3A4 inhibitor. Reviva believes that a full battery of regulatory compliant toxicology and safety pharmacology studies has been completed for brilaroxazine. Reviva intends to develop brilaroxazine for other neuropsychiatric indications including bipolar disorder, major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD).
Additionally, brilaroxazine has shown promising nonclinical activity for inflammatory diseases psoriasis, pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) with mitigation of fibrosis and inflammation in translational animal models. Brilaroxazine has already received Orphan Drug Designation by the U.S. FDA for the treatment of PAH and IPF conditions.
To learn more about the clinical and preclinical data available for brilaroxazine, please visit revivapharma.com/publications
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s 1-year open label extension (OLE) trial evaluating the long-term safety and tolerability for brilaroxazine in schizophrenia, the registrational Phase 3 RECOVER-2 trial, the Company’s expectations regarding the anticipated clinical profile of its product candidates, including statements regarding anticipated efficacy or safety profile, and those relating to the Company’s expectations, intentions or beliefs regarding matters including product development, clinical and regulatory timelines and expenses, planned or additional studies, planned or potential additional indications for the Company’s product candidates, planned or intended regulatory submissions, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential opportunities for development including partnerships, growth or expansion opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company’s other filings from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
Media Contact:
Kristin Politi
kpoliti@lifescicomms.com
(646) 876-4783
FAQ
What is the significance of Reviva's European Patent EP3244896?
How does brilaroxazine work in treating pulmonary hypertension?
What is the safety profile of brilaroxazine?
What are the recent findings from brilaroxazine studies?
Which markets have granted patents for brilaroxazine besides Europe?
